Virpax Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	10.57	11.08	7.19	2.9	2.56	1.48
Research & Development	5.12	10.76	4.84	1.29	0.62	1.14
Operating Expenses	15.69	21.85	12.03	4.2	3.18	2.63
Operating Income	-15.69	-21.85	-12.03	-4.2	-3.18	-2.63
Interest Expense / Income	0	0	0.09	0.15	0.12	0.01
Other Expense / Income	-0.5	-0.19	-0.06	-0	-	-
Pretax Income	-15.19	-21.65	-12.06	-4.34	-3.31	-2.64
Net Income	-15.19	-21.65	-12.06	-4.34	-3.31	-2.64
Shares Outstanding (Basic)	1	1	1	0	0	0
Shares Outstanding (Diluted)	1	1	1	0	0	0
Shares Change	0.02%	75.37%	114.88%	6.09%	3.18%	-
EPS (Basic)	-12.97	-18.49	-18.10	-14.00	-11.30	-9.30
EPS (Diluted)	-12.97	-18.49	-18.10	-14.00	-11.30	-9.30
Free Cash Flow	-9.85	-17.85	-14.54	-1.38	-1.13	-1.8
Free Cash Flow Per Share	-8.41	-15.24	-21.78	-4.46	-3.86	-6.34
EBITDA	-15.19	-21.65	-11.96	-4.19	-3.18	-2.63
EBIT	-15.19	-21.65	-11.96	-4.19	-3.18	-2.63

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).